

Collaborative Working Project Executive Summary

Published on <https://www.fresenius-kabi.com/gb/>

Supporting the Rheumatology Service at University Hospitals Birmingham NHS Foundation Trust with Pharmacist Staff

Project description:

This collaborative working project will involve funding a band 8a Rheumatology Specialist Pharmacist for 12 months at University Hospitals Birmingham NHS Foundation Trust to enhance patient care and an overall service delivery of medicine as per the recent Get It Right First Time (GIRFT), report recommendations. A dedicated Rheumatology pharmacist at University Hospitals Birmingham NHS Foundation Trust will add value to patient care and service delivery. This 12-month post will also provide evidence to support a business case for a permanent post once this project has ended.

Organisations involved:

Fresenius-Kabi and University Hospitals Birmingham NHS Foundation Trust have contributed resources to this project.

Benefits To Patients:

- Improved patient outcomes due to more clinical resource being available.
- Medicines optimisation to ensure they are on the most appropriate therapy.
- More resource for patient support.
- Greater patient satisfaction with the rheumatology service.

Benefits To University Hospitals Birmingham NHS Foundation Trust:

- Increased capacity for and reduced pressure on the rheumatology service at the trust.
- Potential cost savings resulting from the switch from originator to biosimilar adalimumab.
- Increase in Pharmacist activity
- Evidence to support a business case for a permanent post holder in rheumatology funded by the Trust.

Benefits To Fresenius Kabi Ltd:

- Fresenius Kabi Ltd manufacture and market an adalimumab biosimilar which is available for use at University Hospitals

Birmingham NHS Foundation Trust. It is anticipated that when appropriate patients are switched from originator to biosimilar adalimumab, there is potential that of the currently available adalimumab biosimilars in the UK, Fresenius Kabi could possibly benefit from wider use of their adalimumab biosimilar. Greater understanding of the role of a specialist rheumatology pharmacist.

- Greater understanding of patients' needs.

Start Date: Q4 2022